(Reuters) - The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline's (L:GSK) experimental treatment for a common form of blood cancer. GSK's belantamab...
LONDON (Reuters) - An independent panel to the U.S. Food and Drug Administration on Tuesday voted in favour of approving GlaxoSmithKline's (L:GSK) experimental treatment for a...
(Reuters) - GlaxoSmithKline (L:GSK) said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Buy | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Buy | Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Neutral | Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,324.00 | 2,346.00 | 2,303.00 | -46.00 | -1.94% | 3.73M | London | |||
| 173.60 | 175.75 | 170.70 | +1.70 | +0.99% | 29.27M | London | |||
| 397.45 | 400.35 | 394.00 | -3.55 | -0.89% | 18.53M | London | |||
| 846.20 | 872.80 | 834.40 | -35.40 | -4.01% | 2.94M | London | |||
| 1.306 | 1.31 | 1.282 | +0.020 | +1.55% | 333.00K | London | |||
| 1,444.80 | 1,481.20 | 1,439.80 | -66.8 | -4.42% | 880.71K | London | |||
| 267.60 | 268.60 | 263.10 | +3.00 | +1.13% | 14.09M | London | |||
| 357.50 | 359.00 | 351.00 | +2.50 | +0.70% | 393.17K | London | |||
| 510.60 | 522.60 | 509.80 | -4.80 | -0.93% | 4.37M | London | |||
| 665.00 | 668.00 | 663.00 | -3.00 | -0.45% | 215.03K | London | |||
| 387.30 | 392.50 | 387.30 | -5.80 | -1.48% | 6.73M | London | |||
| 127.20 | 127.80 | 125.40 | -0.20 | -0.16% | 2.06M | London | |||
| 234.00 | 238.00 | 233.00 | -3.00 | -1.27% | 259.30K | London | |||
| 8,268.00 | 8,281.00 | 8,180.00 | -9.0 | -0.11% | 2.11M | London | |||
| 1,985.00 | 1,995.00 | 1,935.00 | +35.00 | +1.79% | 42.03K | London |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company’s products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.